PATENT CLAIM ANALYSIS

Application Number: 15960259
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "100000"]

Abstract:
The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R 1 -R 3  are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Claim (Index 55):
A method of treating a cancer selected from the group consisting of B-RAF mutated cancer, a central nervous system tumor, chronic myeloid leukemia, pancreatic cancer, neural cancer, glioma, neuroblastoma, retinoblastoma, ovarian cancer, thyroid cancer, colorectal cancer, melanoma, breast cancer and lung cancer, comprising administering to a subject in need thereof a compound of Formula (1): or a pharmaceutically acceptable salt or ester thereof, wherein:\n R 1  is H; \n R 2  is a moiety selected from the group consisting of H and trifluoromethylcarbonyl; \n or R 1  and R 2  are taken together with the core structure to form a heterocyclydiyl moiety of formula (a): R 3  is a moiety selected from the group consisting of \u2212OR a  and \u2014NR b R c ; R a  is a C 1-4  alkyl group optionally substituted with an imidazolyl; R b  is a moiety selected from the group consisting of a C 1-4  alkyl group and a C 1-4  alkoxy group, wherein R b  is substituted with 0, 1 or 2 groups each independently selected from the group consisting of \u2014OCH 3 , \u2014C(O)OH, \u2014C(O)NR\u2032R\u2033, \u2014NH(C 1-3  alkyl), \u2014NH(CH 2 CH 2 O) n CH 3 , wherein n is 2-4, piperazinyl, N-methylpiperazinyl, piperidinyl, N-methylpiperidinyl, N-morpholinyl, imidazolyl, pyrrolidinyl, \u2014OPO 3 H 2  and hydroxyl; wherein the \u2014NH(C 1-3  alkyl) group is substituted with 0, 1 or 2 hydroxyl moieties and wherein R\u2032 and R\u2033 are each independently selected from \u2014H or \u2014CH 3 ; and R c  is H, or R b  and R c  are taken together with the nitrogen to which they are attached to form a heterocyclyl moiety selected from the group consisting of formula (b) and formula (c): or a pharmaceutically acceptable salt or ester thereof; in an amount effective for treating said B-RAF mutated cancer, a central nervous system tumor, chronic myeloid leukemia, pancreatic cancer, neural cancer, glioma, neuroblastoma, retinoblastoma, ovarian cancer, thyroid cancer, colorectal cancer, melanoma, breast cancer or lung cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 91.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13794635', '12180408', '12595357', '14026591', '13976876']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.778440576449628
- 35 USC 102 Novelty (BERT): 0.5536907766787453
- Combined Prediction Score: 0.7559655964725398
- Mean Citation Score: 334.7711240000001
- Max Citation Score: 423.09964
- Similarity Product: 336.1279972632408

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test